Ipilimumab-Associated Retinopathy.
Ophthalmic Surg Lasers Imaging Retina
; 46(6): 658-60, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-26114847
ABSTRACT
Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Descolamento Retiniano
/
Imunoterapia
/
Anticorpos Monoclonais
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Ophthalmic Surg Lasers Imaging Retina
Ano de publicação:
2015
Tipo de documento:
Article